

## PATENT COOPERATION TREATY

T O F

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

COOLEY GODWARD KRONISH  
Attn. Ford, Timothy D.  
1200 19th Street NW, 5th Floor  
Washington DC 20036  
ETATS-UNIS D'AMERIQUE

## INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

REGISTERED MAIL

Date of mailing (day/month/year)	26/03/2007
Applicant's or agent's file reference BSCI02100WO	<b>PAYMENT DUE</b> within ONE MONTH from the above date of mailing
International application No. PCT/US2007/060581	International filing date (day/month/year) 16/01/2007
Applicant BOSTON SCIENTIFIC SCIMED, INC.	

## 1. This International Searching Authority

- (i) considers that there are 7 (number of) inventions claimed in the international application covered by the claims indicated ~~below~~ on the extra sheet:

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated ~~below~~ on the extra sheet:

- (ii) ☒ has carried out a partial international search (see Annex) ☐ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.:  
see annex

- (iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid

## 2. The applicant is hereby invited, within the time limit indicated above, to pay the amount indicated below:

EUR 1.615,00 x 6 = EUR 9.690  
Fee per additional invention      number of additional inventions      total amount of additional fees

Or, \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☐ Claim(s) Nos. \_\_\_\_\_ have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the International Searching Authority  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Vera Schertl

RECEIVED

APR 02 2007

ENTERED 4.2.07  
DUE: Search Fees

COOLEY GODWARD KRONISH LLP

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2, 3, 15-20, 21, 22

A stent comprising a drug  
---

2. claims: 1, 4-6, 21, 23

A patch comprising a drug  
---

3. claims: 1, 7, 8, 21, 24

A microsphere comprising a drug  
---

4. claims: 1, 9, 10, 21, 25

A solidifying spray solution comprising a drug  
---

5. claims: 1, 11, 21, 26

An injectable gel comprising a drug  
---

6. claims: 1, 12, 13, 21, 27

An injectable paste comprising a drug  
---

7. claims: 1, 14, 21, 28

An implantable plug comprising a drug  
---

This Authority considers that there are 7 inventions covered by the claims indicated as follows:

- I: Claims 1, 2, 3, 15-20, 21, 22 directed to a stent comprising a drug  
II: Claims 1, 4-6, 21, 23 directed to a patch comprising a drug  
II: Claims 1, 7, 8, 21, 24 directed to a microsphere comprising a drug  
IV: Claims 1, 9, 10, 21, 25 directed to a solidifying spray solution comprising a drug  
V: Claims 1, 11, 21, 26 directed to an injectable gel comprising a drug  
VI: Claims 1, 12, 13, 21, 27 directed to an injectable paste comprising a drug  
VII: Claims 1, 14, 21, 28 directed to an implantable plug comprising a drug

The reasons for which the inventions are not so linked as to form a single general inventive concept, as required by Rule 13.1 PCT, are as follows:

The technical features of the independent claims 1 and 21 are a carrier and an agent formulated to control inflammation provided on the carrier. Claims 1 and 21 are not novel since the features therein disclosed are already known from the prior art (e.g. WO-A-01/67991). Moreover, the concept of providing a drug on a carrier to control inflammation in order to improve the healing process is also already known from the prior art (e.g. WO-A-01/67991). Therefore, lack of unity a posteriori arises since the above groups of claims are neither linked by novel and inventive features nor by a common inventive concept. In conclusion, the groups of claims define 7 different inventions.

The application, hence does not meet the requirements of unity of invention as defined in Rules 13.1 and 13.2 PCT.